A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

The brands Rybelsus and Ozempic are currently FDA-approved for diabetes management, and Wegovy is used to assist with weight loss ... received 2.4mg injections of semaglutide each week, and ...

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved similar weight loss to that reported in clinical trials ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...